Zhiming Wang, PhD
Zhiming received his master's degree from the Institute of Microbiology and his Ph.D. from the Institute of Zoology, both at the Chinese Academy of Sciences. After earning his Ph.D., he began postdoctoral training at MD Anderson Cancer Center. He subsequently joined Dr. Li's lab at Houston Methodist. His research focuses on cancer biology and pharmacological targeting of residual tumors, with a particular emphasis on triple-negative breast cancer.
Yuanhui Liu, MD, PhD
Yuanhui received his M.D. with honors from Wuhan University. He then pursued his Ph.D. in the Cancer Biology program at Pierre and Marie Curie University (Paris VI) before joining Dr. Li's lab as a postdoctoral fellow. Yuanhui has expertise in both experimental and computational biology. He is the first author of our study on mTOR published in Nature Communications. Currently, Yuanhui is investigating the molecular regulation of therapy-induced senescence and dissecting novel cell death pathways using CRISPR library screening approaches.
Shaoyang Zhao, PhD
Shaoyang received his Ph.D. from the University of Science and Technology of China. His doctoral research focused on inflammatory bowel disease (IBD) using zebrafish genetic models. His current research explores the modulation of novel cell death pathways to enhance the efficacy of chemotherapy and targeted therapy in both solid tumors and leukemias.